131020-50-3

Basic information

• Product Name: 1H-Benzimidazole-6-carboxylicacid,1-methyl-,methylester(9CI)
• Synonyms: 1H-Benzimidazole-6-carboxylicacid,1-methyl-,methylester(9CI)
• CAS NO: 131020-50-3
• Molecular Formula: C10H10N2O2
• Molecular Weight: 190.2
• Product Categories: BENZIMIDAZOLE
• Mol File: 131020-50-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1H-Benzimidazole-6-carboxylicacid,1-methyl-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-6-carboxylicacid,1-methyl-,methylester(9CI)(131020-50-3)
• EPA Substance Registry System: 1H-Benzimidazole-6-carboxylicacid,1-methyl-,methylester(9CI)(131020-50-3)

Safety Data

• Hazardous Substances Data: 131020-50-3(Hazardous Substances Data)

Usage

General Description

1H-Benzimidazole-6-carboxylic acid, 1-methyl-, methyl ester (9CI) is a chemical compound with the molecular formula C10H9N2O2. It is a derivative of benzimidazole, which is a heterocyclic aromatic organic compound. This specific compound is the methyl ester of 1-methyl-1H-benzimidazole-6-carboxylic acid. It is commonly used in organic synthesis and pharmaceutical research, and it may have potential applications in the development of new drugs. As a methyl ester, it is a colorless to pale yellow liquid with a fruity odor, and it is flammable. It should be handled and stored with proper care to ensure safety.

Upstream product

• 185629-31-6 methyl 3-fluoro-4-nitrobenzoate 
• 26663-77-4 methyl 1H-benzo[d]imidazole-6-carboxylate 
• 74-88-4 methyl iodide 
• 251643-13-7 methyl 3-(methylamino)-4-nitrobenzoate 
• 64-18-6 formic acid 
• 616224-38-5 methyl 4-amino-3-(methylamino)benzoate 

Downstream Products

• 53484-18-7 1-methyl-6-benzimidazole carboxylic acid 

Relevant articles and documents

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure-activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.

Synthesis and antiprotozoal activity of nitazoxanide-N-methylbenzimidazole hybrids

A series of a novel hybrid compounds between nitazoxanide and N-methylbenzimidazole were synthesized starting from the corresponding N-methyl-2-nitroanilines. The new hybrid compounds (1-13) were evaluated in vitro against Giardia intestinalis, Entamoeba

Neutrophil inhibitors to reduce inflammatory response

The invention provides novel compounds selected from the group consisting of: The compounds of the present invention are useful for the treatment and prevention of a variety of diseases and conditions associated with undesirable or abnormal inflammatory responses, such as ischemia-reperfusion injury. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment or prevention for the above disorders using theses compounds or the compositions containing them.